SQZ Biotechnologies’ Market continues Uptrend, following last week’s FDA Fast Track Designation announcement – 247MarketNews.com

SQZ Biotechnologies’ Market continues Uptrend, following last week’s FDA Fast Track Designation announcement

On April 27, 2022, after the market closed, SQZ Biotechnologies (NYSE:SQZ) announced that the FDA granted Fast Track Designation for the company’s lead cell therapy candidate, SQZ-PBMC-HPV, for the treatment of HPV16+ advanced or metastatic solid tumors.

The Fast Track Designation potentially allows SQZ to sell its SQZ Antigen Presenting Cells product candidate to patients earlier and accelerate the development and review of treatments for serious and life-threatening diseases where no treatment currently exists or where the treatment in discovery may be better than what is currently available.

Click here for the SQZ press release

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.